Business

Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine

Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, and Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, today announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The collaboration will leverage Lunit's AI technology and Agilent's expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker

articleLunit Inc.September 22, 20253/company/lunit-inc/news/lunit-and-agilent-technologies-announce-collaboration-to-enhance-development-of-companion-diagnostic-solutions-powered-with-ai-for-precision-medicine
Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine

About this update from Lunit Inc.

[{"type":"text","content":"Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities ","length":167,"tagName":"p"},{"type":"text","content":"SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, and Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, today announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The collaboration will leverage Lunit's AI technology and Agilent's expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.","length":587,"tagName":"p"},{"type":"image","alt":"Lunit and Agilent Technologies announce a collaboration to develop AI-powered companion diagnostics. (Courtesy of Lunit)","displaySize":"","headline":null,"caption":"Lunit and Agilent Technologies announce a collaboration to develop AI-powered companion diagnostics. (Courtesy of Lunit)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":222,"url":"https://media.zenfs.com/en/prnewswire.com/b6905755f5efd4f99fbf471711a3ee5c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OUW14Wor.fk7NS.30x07tQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b6905755f5efd4f99fbf471711a3ee5c","width":400,"height":222}},"href":"https://mma.prnewswire.com/media/2778296/Lunit_Agilent_Technologies_announce_a_collaboration_develop_AI_powered_companion_diagnostics.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under this agreement, Lunit and Agilent will develop advanced AI-powered companion diagnostic tools designed to enhance the accuracy of diagnosis and the measurement of therapeutic efficacy. The initial focus will be on leveraging Lunit's AI algorithms with Agilent's state-of-the-art assays to evaluate biomarkers critical for the development of new pharmaceutical therapies.","length":389,"tagName":"p"},{"type":"text","content":"The joint solutions will support pharmaceutical companies in companion diagnostic (CDx) product development, improving the precision and accuracy of biomarker t...

More updates from Lunit Inc.

Agilent Technologies Inc.companion diagnosticsdiagnostic solutionscancer diagnosticsAI algorithmsLunitproduct developmentadvanced solutionscompanion diagnosticprecision and accuracy